GlobeNewsWire
13 Jun 2026, 16:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Epcoritamab combined with R-mini-CHOP demonstrated a 93% overall response rate and 86% complete response rate in elderly patients with newly diagnosed DLBCL. — Extremely high response rates in a difficult-to-treat population suggest a potential new standard of care and significant commercial expansion.
+0.80Epcoritamab monotherapy achieved a 67% overall response rate and 58% complete response rate for elderly DLBCL patients ineligible for standard chemotherapy. — Provides a viable alternative for a high unmet medical need population, expanding the drug's addressable market.
+0.60Phase 2 data for epcoritamab monotherapy showed a median progression-free survival of 13.0 months with 62% of patients alive at 18 months. — Provides clinical validation of durability, which is critical for regulatory approval and reimbursement.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
The safety profile for epcoritamab in elderly patients included a 71% rate of cytokine release syndrome (CRS) and 18% rate of ICANS. — While consistent with expectations for this drug class, high incidence of side effects in a 'fragile' population may limit uptake or complicate administration.
-0.20Which stocks this story touches
The company announced high response rates and positive clinical data for epcoritamab in elderly patients with DLBCL.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
17h ago
